CARDINAL HEALTH INC Q2 FY2025 earnings call

Jason mentioned strong second quarter results led by Pharma and Specialty Solutions, with acceleration of strategy, execution of simplification, and positive performance despite Q2 being below expectations in GMPD. Aaron highlighted financial momentum in Q2, growth in operating earnings, raised EPS guidance, and reviewed results by segment, including Pharma's strong performance, GMPD's progress on improvement plan, and other businesses' robust demand. Also mentioned the closing of acquisitions of ION and GI Alliance and capital deployment plans.

Total company revenue decreased 4% to $55 billion on a reported basis. Adjusting for the contract expiration, revenue increased 16% versus the prior year, primarily reflecting strong demand across pharma and all three of the businesses included in other. Pharma segment: Q2 Pharma segment revenue decreased 4% to $51 billion, but excluding contract expiration, revenue increased 16% vs prior year; segment profit increased 7% to $531 million. GMPD segment: Revenue increased 1% to $3.2 billion, segment profit increased to $18 million but slightly below expectations. Other businesses (at-Home, Nuclear, OptiFreight): Revenue increased 13% to $1.3 billion, collectively grew segment profit by 11%, driven by OptiFreight and Nuclear.

Raised EPS guidance to a range of $7.85 to $8. For Pharma, improving revenue outlook to a decline of 1% to 3%, with midpoint 20% growth; raising Pharma segment profit guidance to 10% to 12% growth. GMPD revenue growth unchanged at 2% to 4%. Other business reiterates 10% to 12% revenue growth and approximately 10% segment profit.

Scrutinizing volume trends and the current highly fluid tariff environment in Mexico and the United States, awaiting clarity on industry-wide dislocations or exceptions which may present both risks and opportunities.

Q: John Stansel from JPMorgan asked about high single-digit operating profit growth in Pharma ex-M&A and growth second half fiscal '25 excluding M&A.

A: Aaron Alt responded on the enterprise results, Pharma business performance, first half utilization environment, back half onboarding of new customers, and lapping of Specialty Networks acquisition.

Q: Erin Wright from Morgan Stanley asked about what's seen across specialty, key drivers, and integration of assets.

A: Jason Hollar talked about specialty being a driver of revenue and profit, broad-based specialty growth, strategy centered on community provider, and two distinct platforms in Oncology and multi-specialty.

Q: Allen Lutz from Bank of America asked about COVID vaccine volumes in Q2.

A: Aaron Alt said COVID vaccine volumes in Q2 came in exactly as expected, a modest headwind.

Q: Elizabeth Anderson from Evercore asked about GMPD, cadence of investments, and opportunity.

A: Aaron Alt and Jason Hollar discussed GMPD's guidance, progress on improvement plan, impact of healthcare costs, WaveMark charge, and tariffs.

Q: Michael Cherny from Leerink Partners asked about specialty commentary, integration resonating in the market, and accelerating growth.

A: Jason Hollar talked about specialty being a partner of choice, growth in specialty revenue, and further improving capabilities.

Q: Eric Percher from Nephron asked about Cardinal brand growth and impact on at-Home.

A: Jason Hollar said Cardinal brand still growing with slight growth, and at-Home has strong revenue growth with investments in automation and efficiency.

Q: Kevin Caliendo from UBS asked about utilization, comping higher utilization, and driver of higher utilization.

A: Jason Hollar and Aaron Alt discussed drivers of earnings, volume growth, productivity, and normalization of growth drivers.

Q: Eric Coldwell from Baird asked about GI Alliance and med-surg opportunity.

A: Jason Hollar said there's med-surg opportunity but focused on GI Alliance's role in non-oncology therapeutic areas.

Q: Daniel Grosslight from Citi asked about segregation of products made in US and Mexico, and onshoring strategy.

A: Jason Hollar talked about breakdown of product manufacturing, onshoring capabilities, and considerations with tariffs.

Q: Steven Valiquette from Mizuho asked about flu/illness season impact on GMPD and company.

A: Jason Hollar said it's too early to tell on flu/illness season impact, watching trends closely.

Q: Charles Rhyee from TD Cowen asked about onshoring plans and generic environment.

A: Jason Hollar and Aaron Alt discussed onshoring considerations, cost trade-offs, and consistent market dynamics in generics.

Q: Jack Slevin from Jefferies asked about cash flow, credit rating, and capital allocation.

A: Aaron Alt talked about disciplined capital allocation strategy, protecting investment-grade rating, and managing debt to get back within leverage range.